EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Navigating the hurdles: Parents' experiences of Elexacaftor/Tezacaftor/Ivacaftor during the early phase of treatment in young children with CF

Sioned H Davies iD, Annabel Taylor iD, Simon Curran, Cliona McRobert iD, Heather Fogg, Adam Walsh iD, Kevin W Southern

Chronic Illness · 14.11.2026

DOI: 10.1177/17423953261491386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chronic Illness, online erschienen am 14.11.2026. Verfasst von Sioned H Davies und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Allied Health Professions and Nursing, University of Liverpool, Liverpool, UK. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR student internship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

CFTR modulator therapy has changed the landscape of Cystic Fibrosis care with reports of improved quality of life and physiological markers for adults and adolescents with Cystic Fibrosis (CF), however little is known about the lived experience of caregivers. This study explored parents’ experiences of initiating elexacaftor/tezacaftor/ivacaftor (ETI) in young children with CF in the United Kingdom.

Method

Three focus groups facilitated by a topic guide were conducted with parents via Microsoft Teams. The focus groups were recorded and transcribed, and thematic analysis was used to identify the main themes.

Results

Thirteen participants (10 mothers and three fathers) participated. Four main themes were identified: (1) Navigating the hurdles; The feeling of parental responsibility when starting a new medication (2) “It's just one giant guessing game: Is it the medication, or is it my child?” (3) “It is a payoff” benefit observed outweighing the potential side effects for parents (4) Beyond the clinical trials; the practicalities of caring for a young child on ETI.

Discussion

Starting a new medication is a considered, balanced decision for families, with significant parental responsibility felt emotionally and practically. Clinical teams must work collaboratively with families to support decision-making and monitor young children while introducing new therapies.

Schlagwörter

Stichwörter der Autor:innen

Cystic fibrosismodulator therapypaediatricparentqualitative

Autor:innen und Institutionen

  • School of Allied Health Professions and Nursing, University of Liverpool, Liverpool, UK.
  • Alder Hey Children's NHS Foundation Trust Alder Hey Children's Hospital, Liverpool, UK.

ORCID-Profile: Sioned H Davies, Annabel Taylor, Cliona McRobert, Adam Walsh

Förderung

  • NIHR student internship

Zitieren

APA

Davies, S. H., Taylor, A., Curran, S., McRobert, C., Fogg, H., Walsh, A., & Southern, K. W. (2026). Navigating the hurdles: Parents' experiences of Elexacaftor/Tezacaftor/Ivacaftor during the early phase of treatment in young children with CF. Chronic Illness. https://doi.org/10.1177/17423953261491386

Vancouver

Davies SH, Taylor A, Curran S, McRobert C, Fogg H, Walsh A, et al. Navigating the hurdles: Parents' experiences of Elexacaftor/Tezacaftor/Ivacaftor during the early phase of treatment in young children with CF. Chronic Illness. 2026. doi:10.1177/17423953261491386

BibTeX
@article{Davies2026,
  author = {Davies, Sioned H and Taylor, Annabel and Curran, Simon and McRobert, Cliona and Fogg, Heather and Walsh, Adam and Southern, Kevin W},
  title = {Navigating the hurdles: Parents' experiences of Elexacaftor/Tezacaftor/Ivacaftor during the early phase of treatment in young children with CF},
  journal = {Chronic Illness},
  year = {2026},
  doi = {10.1177/17423953261491386}
}
Kostenlos starten →